'On consolidated basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has declined 1.16% to Rs 805.17 crore. Operating profit margin has jumped from 28.30% to 31.20%, leading to 8.96% rise in operating profit to Rs 251.20 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 16.65% to 14.59%. Purchase of finished goods cost rose from 20.80% to 26.44%. Employee cost decreased from 18.22% to 17.39%. Other expenses fell from 16.57% to 12.95%.
Other income rose 22.67% to Rs 43.72 crore. PBIDT rose 10.80% to Rs 294.92 crore. Provision for interest rose 13.51% to Rs 0.42 crore.
PBDT rose 10.79% to Rs 294.5 crore. Provision for depreciation fell 5.42% to Rs 15.52 crore.
Profit before tax grew 1...
Pleaselogin & subscribe to view the full report.
More Reports
-
(13-Jan-2026)
HCL Technologies
Revenue up 13.3% YoY to Rs 33872 crore in Q3FY2026
-
(13-Jan-2026)
Tata Consultancy Services
Revenue up 4.9% YoY to Rs 67087 crore in Q3FY2026
-
(12-Jan-2026)
Krishana Phoschem
Revenue up 116.8% YoY to Rs 659 crore in Q3FY2026
-
(11-Jan-2026)
Avenue Supermarts
Revenue up 13.3% YoY to Rs 18100.9 crore, Net profit up 18.3% yoy to Rs 855.9 crore in Q3FY2026
|
|